President Donald Trump announced nine of the largest drugmakers in the U.S. and Europe agreed to voluntarily sell their ...

The White House announced Friday that nine additional pharmaceutical companies have agreed to follow President Trump’s “most ...

Deals between pharmaceutical companies and Washington to reduce prices for medicines in the United States will likely push up ...

Genentech, a subsidiary of the Roche Group, has received the US FDA accelerated approval for Lunsumio VELO SC formulation to ...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...

Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward ...

The US FDA has approved a subcutaneous version of Roche (RHHBY)-owned Genentech's follicular lymphoma treatment, Lunsumio ...

The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar ...

– Approval supported by data demonstrating compelling complete response rate in third-line or later follicular lymphoma, which typically becomes harder to treat after each relapse – Genentech, a ...

The FDA approved a new 300 mg/2 mL dose of Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of four allergic and ...

Here are seven biopharma-related trends for 2026 that have emerged from GEN interviews with experts and other industry stakeholders, and from reviews of reports and public statements.

The agreement will lower the cost of certain drugs for asthma, some cancers, HIV and Type 2 diabetes, among other conditions.